Related Experiment Videos
Insights
Calcium antagonists show mixed results in heart failure treatment. Newer, more selective agents may benefit patients with coronary artery disease and hypertension, but verapamil is not recommended for severe heart failure.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Calcium antagonists (CAs) have shown beneficial acute hemodynamic effects in heart failure (HF).
- However, their use in HF remains controversial due to potential negative inotropic effects.
- Autonomic reflexes modulate direct effects of CAs, influencing their clinical utility.
Purpose:
- To evaluate the role and safety of calcium antagonists in managing heart failure.
- To compare the effects of different calcium antagonists on myocardial contractility and hemodynamics.
- To assess the potential benefits of newer, vasoselective calcium antagonists in heart failure.
Summary:
- Direct negative inotropic effects of CAs can be counterbalanced by baroreceptor-mediated reflexes, especially with nifedipine and diltiazem.
- Verapamil may cause significant depression of contractility, making it unsuitable for severe heart failure.
- Newer vasoselective CAs like nisoldipine and felodipine offer pronounced arterial vasodilation with minimal myocardial effects, potentially benefiting HF patients with comorbidities.
Impact:
- Newer calcium antagonists may be advantageous for heart failure patients with coronary artery disease and hypertension.
- Preliminary data suggest potential long-term benefits in selected heart failure patients.
- Verapamil should be avoided in severe heart failure due to the risk of left ventricular (LV) function deterioration.
Abstract:
Although beneficial acute hemodynamic effects of calcium antagonists in heart failure have been reported, their use in this setting is still controversial because of the negative inotropic effects produced by these agents. The direct actions of calcium antagonists, that is direct depression of myocardial contractility and coronary and peripheral vasodilation, are modulated by systemic hypotension-induced baroreceptor activation of autonomic reflexes. Thus, at clinically relevant dosages, the baroreceptor-mediated cardiac stimulatory effects may counterbalance or override the direct negative-inotropic effects, as usually observed with nifedipine or diltiazem. By contrast, with verapamil significant depression of contractility may occur. Newer calcium antagonists with higher vasoselectivity such as nisoldipine or felodipine may be particularly interesting in the setting of congestive heart failure because of pronounced arterial vasodilatation and their additional effects on coronary blood flow, LV-regional wall motion and diastolic function and peripheral blood flow distribution with negligible myocardial effects. Due to their marked vasodilatating properties, newer derivatives may be advantageous in the treatment of heart failure due to coronary artery disease and hypertension. Although limited data concerning long-term efficacy are available, preliminary studies suggest long-term benefit in selected patients. It appears that verapamil should not be used for vasodilator therapy of severe heart failure, since deterioration of LV function may occur.